Healthcare

Healthcare

CytoDyn (OTC: CYDY)Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)

March 12, 2019 admin Comments Off on CytoDyn (OTC: CYDY)Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)

VANCOUVER, Washington, March 11, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that leronlimab (PRO 140), […]

Healthcare

FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

March 7, 2019 admin Comments Off on FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

VANCOUVER, Washington, March 04, 2019 — CytoDyn Inc. (otc.qb:CYDY), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the FDA has reviewed […]

Healthcare

CytoDyn (OTC: CYDY) to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019

February 28, 2019 admin Comments Off on CytoDyn (OTC: CYDY) to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019

VANCOUVER, Washington, Feb. 27, 2019 — CytoDyn Inc. (OTC.QB: CYDY), a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that data from its study of leronlimab […]

CEO Interview

Ventripoint Diagnostics (TSX. V: VPT) (OTC: VPTDF) AI-driven medical imaging technology for cardio and cancer markets

February 27, 2019 admin Comments Off on Ventripoint Diagnostics (TSX. V: VPT) (OTC: VPTDF) AI-driven medical imaging technology for cardio and cancer markets

                  Ventripoint Diagnostics (TSX. V: VPT) (OTC: VPTDF) interview with Dr. George Adams, CEO, discussing the company’s innovative AI-driven medical imaging technology addressing the cardio and cancer markets. […]

Healthcare

CytoDyn’s (OTC: CYDY) Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks

February 20, 2019 admin Comments Off on CytoDyn’s (OTC: CYDY) Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks

Based on strong results in its pre-clinical animal study, CytoDyn files for Orphan Drug Designation for Triple-Negative Breast Cancer VANCOUVER, Washington, Feb 20, 2019 – CytoDyn Inc. (otc.qb:CYDY), a biotechnology company developing a novel humanized […]

Healthcare

CytoDyn (OTC: CYDY) Announces Productive Conference Call with FDA Regarding First BLA Submission for Leronlimab (PRO 140) Combination Therapy at 700 mg Dose

February 7, 2019 admin Comments Off on CytoDyn (OTC: CYDY) Announces Productive Conference Call with FDA Regarding First BLA Submission for Leronlimab (PRO 140) Combination Therapy at 700 mg Dose

VANCOUVER, Washington, Feb 01, 2019 — Successful interim results in the 700 mg monotherapy arm prompted the FDA to allow CytoDyn to switch all remaining combination therapy patients from CD02-Extension study from 350 mg to […]

CEO Interview

Generex Biotechnology Corp. (OTC: GNBT): Building a billion dollar next-generation healthcare business.

January 11, 2019 admin Comments Off on Generex Biotechnology Corp. (OTC: GNBT): Building a billion dollar next-generation healthcare business.

                Generex Biotechnology Corp. (OTC: GNBT) Interview with CEO Joe Moscato. Joe shares an update on the continued transformation of Generex into a next-generation integrated pharmaceutical healthcare business, through […]

CEO Interview

Trendlines Group, Ltd.  (OTC: TRNLY) Delivering 10X returns on Israeli medical and agricultural innovation

December 24, 2018 admin Comments Off on Trendlines Group, Ltd.  (OTC: TRNLY) Delivering 10X returns on Israeli medical and agricultural innovation

              Trendlines Group, Ltd.  (OTC: TRNLY) (Singapore: 42T), interview with co-CEO/Chairman Steve Rhodes, discussing the company’s investment strategy in early-stage medical and agricultural innovation companies in Israel and Singapore. Since […]

CEO Interview

BrainStorm Cell Therapeutics (NASDAQ: BCLI) Stem cell therapy for ALS in Phase III FDA trials

December 23, 2018 admin Comments Off on BrainStorm Cell Therapeutics (NASDAQ: BCLI) Stem cell therapy for ALS in Phase III FDA trials

      BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) interview with CEO, Chaim Lebovits, discussing the company’s advancements in developing stem cell therapies to treat neurodegenerative diseases. The company’s pipeline includes a lead indication for ALS- Amyotrophic Lateral […]

Healthcare

DECN Subsidiaries Appeal Nevada District Court Trial Judge’s Ruling to U.S. Court of Appeals for the Federal Circuit (The Patent Appeals Court)

December 21, 2018 admin Comments Off on DECN Subsidiaries Appeal Nevada District Court Trial Judge’s Ruling to U.S. Court of Appeals for the Federal Circuit (The Patent Appeals Court)

Companies Anticipate Another Precedential Ruling from the Federal Circuit Three Judge Panel Based on One Over-Arching Argument LOS ANGELES, CA / ACCESSWIRE / December 19, 2018 / Decision Diagnostics Corp. (otc pink:DECN) Decision Diagnostics Corp. […]

CEO Interview

Pluristem Therapeutics, Inc. (NASDAQ: PSTI) Regenerative medicine technologies for billion dollar markets

December 20, 2018 admin Comments Off on Pluristem Therapeutics, Inc. (NASDAQ: PSTI) Regenerative medicine technologies for billion dollar markets

            Pluristem Therapeutics, Inc. (NASDAQ: PSTI), interview with co-CEO Yaky Yanay. Yaky explains Pluristem’s regenerative medicine technologies, which use placenta-derived cell products, and address multi-billion health markets. Pluristem has 3 […]